Alexi Vasbinder PhD, RN , Christopher W. Hoeger MD , Tonimarie Catalan BS , Elizabeth Anderson MPH , Catherine Chu MD , Megan Kotzin BS , Jeffrey Xie MD, PhD , Rayan Kaakati MD , Hanna P. Berlin MD , Husam Shadid MD , Daniel Perry MD , Michael Pan MD , Radhika Takiar MD , Kishan Padalia MD , Jamie Mills MD, PhD , Chelsea Meloche MD , Alina Bardwell BS , Matthew Rochlen , Pennelope Blakely BS , Monika Leja MD , Salim S. Hayek MD
{"title":"Cardiovascular Events After Hematopoietic Stem Cell Transplant","authors":"Alexi Vasbinder PhD, RN , Christopher W. Hoeger MD , Tonimarie Catalan BS , Elizabeth Anderson MPH , Catherine Chu MD , Megan Kotzin BS , Jeffrey Xie MD, PhD , Rayan Kaakati MD , Hanna P. Berlin MD , Husam Shadid MD , Daniel Perry MD , Michael Pan MD , Radhika Takiar MD , Kishan Padalia MD , Jamie Mills MD, PhD , Chelsea Meloche MD , Alina Bardwell BS , Matthew Rochlen , Pennelope Blakely BS , Monika Leja MD , Salim S. Hayek MD","doi":"10.1016/j.jaccao.2023.07.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications.</p></div><div><h3>Objectives</h3><p>We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients.</p></div><div><h3>Methods</h3><p>We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT).</p></div><div><h3>Results</h3><p>In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; <em>P =</em> 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events.</p></div><div><h3>Conclusions</h3><p>The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":null,"pages":null},"PeriodicalIF":12.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087323002399/pdfft?md5=60ebc83492bca35efb89a46cd1aa5d7a&pid=1-s2.0-S2666087323002399-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087323002399","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications.
Objectives
We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients.
Methods
We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT).
Results
In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; P = 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events.
Conclusions
The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
期刊介绍:
JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge.
The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention.
Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.